Fort Washington Investment Advisors Inc. OH Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Fort Washington Investment Advisors Inc. OH boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.8% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,533 shares of the company's stock after purchasing an additional 307 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Eli Lilly and Company were worth $2,092,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mogy Joel R Investment Counsel Inc. boosted its stake in Eli Lilly and Company by 11.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 39,001 shares of the company's stock valued at $32,211,000 after acquiring an additional 3,993 shares during the last quarter. Allen Mooney & Barnes Investment Advisors LLC boosted its stake in Eli Lilly and Company by 1.7% in the first quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 5,336 shares of the company's stock valued at $4,407,000 after acquiring an additional 88 shares during the last quarter. Sterling Financial Group Inc. boosted its stake in Eli Lilly and Company by 8.7% in the first quarter. Sterling Financial Group Inc. now owns 412 shares of the company's stock valued at $340,000 after acquiring an additional 33 shares during the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in Eli Lilly and Company by 1.3% in the first quarter. Ferguson Wellman Capital Management Inc. now owns 21,098 shares of the company's stock valued at $17,425,000 after acquiring an additional 278 shares during the last quarter. Finally, Defined Financial Planning LLC lifted its stake in shares of Eli Lilly and Company by 6.6% during the 1st quarter. Defined Financial Planning LLC now owns 421 shares of the company's stock valued at $339,000 after buying an additional 26 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 0.8%

Shares of LLY stock traded up $6.53 on Friday, hitting $818.56. 2,753,537 shares of the company's stock traded hands, compared to its average volume of 3,658,306. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company's fifty day simple moving average is $775.43 and its 200 day simple moving average is $801.59. The stock has a market capitalization of $775.78 billion, a price-to-earnings ratio of 69.90, a P/E/G ratio of 1.40 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business posted $2.58 EPS. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Ratings Changes

A number of brokerages recently commented on LLY. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.